Testosterone cypionate: how long it lasts, how it is dosed, and what to monitor

A six-day modelled half-life, a peak two days after the injection, and a panel that changes in fairly predictable ways. What the ester actually does, and what the numbers on the follow-up bloodwork are answering.

The ester is the whole reason the schedule works

Testosterone cypionate is testosterone with a cyclopentylpropionate group attached at the 17-beta position. That group does nothing hormonal. Its job is solubility: it makes the molecule fat-soluble enough to sit in an oil depot in muscle or subcutaneous tissue and leave slowly, and it has to be cleaved off by esterases in the blood before the testosterone underneath can bind an androgen receptor at all. Injected testosterone without an ester is cleared in hours, which is why unesterified suspension has to be given daily and why every practical injectable protocol uses an ester.

The app models cypionate at a six-day half-life with the level peaking around 48 hours after an injection. Published estimates vary more than most people expect — figures between four and eight days appear in the literature, partly because the rate of release from the depot, not the clearance of testosterone itself, is what is being measured, and depot behaviour depends on injection volume, oil carrier and site. Established clinical use The ester chemistry and the depot mechanism are not controversial; the exact half-life figure is a range, and the fact box above reports the app's modelled value rather than a consensus.

One consequence matters more than the number. Because release is slow and continuous, a serum testosterone drawn at an arbitrary time says relatively little on its own. The same person on the same protocol will produce different totals two days after an injection and seven days after it. A result without a stated interval since the last dose is difficult to compare against anything, including their own previous result.

Why weekly and twice-weekly schedules both exist

At a six-day half-life, a weekly injection leaves roughly 44% of each dose still present when the next one arrives, so the level accumulates to somewhere near twice a single dose before it plateaus — about a month in. Splitting the same weekly amount into two injections does not change the average level at all. It changes the swing: half the amount, half as far to fall, so the difference between the highest and lowest point of the week narrows.

Off-label or community practice That is the entire argument behind twice-weekly and every-other-day protocols, and it is a real one for people whose symptoms track the trough — mood, energy or libido sliding in the last two days before the next injection. It is also a real one for people whose estradiol climbs at the peak, since aromatisation scales with the substrate available. What it is not is a way to raise the average level, and it is not automatically better: more injections is more injections, and plenty of people are stable on one a week.

Subcutaneous and intramuscular administration are both in wide clinical use for cypionate. The subcutaneous depot releases somewhat more slowly and flattens the curve a little further; the practical difference for most people is the needle rather than the pharmacokinetics. Which of these applies to a particular person is a prescribing decision, and the schedule in a prescription is usually chosen from symptoms and trough labs rather than from a curve.

What actually changes on the follow-up panel

Four things move reliably, and they are the reason the monitoring panel looks the way it does. Luteinising hormone and FSH fall, usually to unmeasurable, because exogenous testosterone suppresses the hypothalamic-pituitary signal — that is expected on therapy rather than a finding. Haematocrit rises, sometimes substantially. Estradiol rises roughly in proportion to testosterone, because aromatase converts some of it. And SHBG usually falls, which is why free testosterone can move differently from total.

Established clinical use Haematocrit is the one with a threshold attached. The Endocrine Society's 2018 guideline recommends measuring it at baseline, again at three to six months, and annually after that, and evaluating a haematocrit above 54% rather than continuing unchanged. Different bodies quote different starting thresholds and the baseline figure is reported inconsistently across sources, but the withholding threshold is where the agreement is.

Estradiol is where the most avoidable harm happens, and the mechanism is straightforward: symptoms of estradiol that is too low overlap almost completely with symptoms of estradiol that is too high — low libido, flat mood, joint discomfort. Treating one as the other on symptoms alone, without a sensitive assay, is how people end up worse. The estradiol page covers why the assay method changes the number.

The curve, the accumulation ratio and the peak-to-trough figures have a page of their own: Testosterone Cypionate half-life and steady state.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Testosterone Cypionate, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Sensitive versus standard estradiol
• Total testosterone
• Free versus total testosterone, and the three ways labs get the free number
• SHBG
• Hematocrit on testosterone therapy

Drawbacks and risks the app records

Reproduced from the app's own entry. This site publishes the drawback list and not the benefits list, on purpose: a risk you have not heard of is worth reading, and a benefits list under a founder's byline on an indexable page is advertising.

• Suppresses natural testosterone (HPTA)
• Can elevate E2 — gynecomastia and water retention
• May raise hematocrit — polycythemia risk
• Testicular atrophy with long-term use
• Potential hair loss in susceptible individuals
• Requires bloodwork every 3-6 months

Interaction rules that name Testosterone Cypionate

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Is cypionate different from enanthate in practice?

Chemically they differ by two carbons on the ester chain, and the app models cypionate at six days against enanthate's four and a half. In clinical use they are treated as interchangeable at equivalent amounts, and guidelines list them together. The carrier oil differs between products more than the esters differ from each other, and that is what people usually notice at the injection site.

When should bloodwork be drawn relative to the injection?

The pharmacokinetic answer is that it does not matter which point you pick as long as you pick the same one every time and write it down, because the comparison across draws is what carries the information. Many clinicians standardise on a trough — immediately before the next dose — for exactly that reason. After any change to the amount or the schedule, the level takes about five half-lives to settle, so roughly a month at this half-life; a panel drawn sooner is measuring something still moving.

Does testosterone therapy shut down natural production permanently?

Suppression of LH and FSH is expected and happens quickly. Recovery after stopping is usual but not guaranteed, and it is slower with longer duration of use and higher amounts. This is a genuinely consequential decision for anyone who wants biological children, and it belongs in a conversation with a clinician before starting rather than after — not in an article.

Why does the app record SHBG on the panel?

Because total testosterone alone can be misleading when SHBG moves. SHBG binds most circulating testosterone; when it falls, a stable total can sit alongside a rising free fraction, and when it is high, a reassuring total can sit alongside a low one. The SHBG page covers how the two relate and why calculated and measured free testosterone disagree.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.